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summary
Although multidrug-resistant (MDR) tuberculosis (TB) is a major public health problem in Eastern
Europe, the factors contributing to emergence, spread and containment of MDR-TB are not well deﬁned.
Here, we analysed the characteristics of drug-resistant TB in a cross-sectional study in Abkhazia
(Georgia) between 2003 and 2005, where standard short-course chemotherapy is supplemented with
individualized drug-resistance therapy. Drug susceptibility testing (DST) and molecular typing were
carried out for Mycobacterium tuberculosis complex strains from consecutive smear-positive TB patients.
Out of 366 patients, 60.4% were resistant to any ﬁrst-line drugs and 21% had MDR-TB. Overall, 25% of all
strains belong to the Beijing genotype, which was found to be strongly associated with the risk of MDR-
TB (OR 25.9, 95% CI 10.2–66.0) and transmission (OR 2.8, 95% CI 1.6–5.0). One dominant MDR Beijing
clone represents 23% of all MDR-TB cases. The level of MDR-TB did not decline during the study period,
coinciding with increasing levels of MDR Beijing strains among previously treated cases.
Standard chemotherapy plus individualized drug-resistance therapy, guided by conventional DST, might
be not sufﬁcient to control MDR-TB in Eastern Europe in light of the spread of ‘‘highly transmissible’’
MDR Beijing strains circulating in the community.
 2009 Elsevier Ltd. All rights reserved.
1. Introduction
Drug-resistant tuberculosis (TB) is a major public health
problem, particularly in countries of the former Soviet Union
affected by economic decline and failing health infrastructures.1–4
Globally, some of these countries show the highest frequency of
isolation of Mycobacterium tuberculosis complex (MTBC) strains of
multidrug-resistant (MDR)-TB, deﬁned as resistance to at least
isoniazid and rifampicin. MDR-TB rates of up to 14% have been
documented, making successful treatment of the disease difﬁ-
cult.5,6 Inadequate treatment is the primary cause of acquired
drug resistance. In most limited-resource countries, MDR-TB cases
are identiﬁed when patients fail to respond to ﬁrst-line TB
therapy.4 Prolonged periods of sputum smear positivity might
then result in enhanced transmission of MDR strains, further
accelerating the increase of MDR-TB incidence.4 Consequently in
countries with high prevalence of resistance, in addition to
standard short-course chemotherapy, rapid diagnosis of resistance
and appropriate treatment regimens are key components for the
control of TB.3
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Interestingly, high levels and spread of MDR-TB in Eastern
Europe have been found to be associated with a speciﬁc phyloge-
netic lineage/genotype of the MTBC, the Beijing genotype, indi-
cating that special properties of this pathogen might also
contribute to the problem of drug resistance.7 Studies have
conﬁrmed that patients infected with Beijing genotype strains have
a higher risk of MDR-TB.3,7,8 Furthermore, Beijing strains may also
contribute to the transmission of MDR-TB.8,9 However, studies on
the consequences of Beijing genotype infection for both TB trans-
mission and drug-resistance in high-incidence regions are only
sparsely available.
Here, we present the results of a cross-sectional survey, which
assessed the characteristics of drug-resistant TB in Abkhazia
(Georgia). We examined the frequency of MDR-TB and XDR-TB, as
well as the relationships among resistant strains, frequency of
Beijing genotype strains, and clustering in the region.
2. Methods
2.1. Study setting
The survey was conducted in 2003–2005 in the Guliripchi TB
hospital of Abkhazia, which is the only TB diagnostic centre in the
region. Abkhazia is an autonomous region of western Georgia.
Since 1994, this region has been in chronic conﬂict with Georgia
and has an approximate population estimated between 150 and
190,000 inhabitants.10 The TB case notiﬁcation rate was 125/
100,000 population in 2001, and 14% of the overall TB population
were infected with MDR-TB strains.11 Me ´decins Sans Frontie `res
(MSF) has supported the treatment of TB patients in Abkhazia since
1999, based on World Health Organization (WHO)/International
Union Against Tuberculosis and Lung Disease (IUATLD) guidelines.
Since 2001, MDR- and polydrug-resistant (resistance to more than
one ﬁrst-line anti-TB drug but non-MDR) TB patients received
second-line drugs. Indeed, beginning with 2001, the policy adopted
was to initiate all TB patients (new or previously treated cases) on
WHO standard short-course chemotherapy. After 2–3 months,
regimens were adapted based on the DST results. The WHO Green
Light Committee approved this treatment program in 2004.
2.2. Study design
All consecutive pulmonary smear-positive TB patients 18 years
or older presenting to the Guliripchi TB Hospital between 2003 and
2005 were enrolled in the survey. The health authorities of
Abkhazia and the Ministry of Health of Georgia approved the study.
Written informed consent was obtained from included patients. TB
case deﬁnitions followed WHO/IUATLD guidelines.
12 Demographic
data, anti-TB treatment history, and prisoner history were recorded
from patients’ ﬁles.
2.3. Cultures and drug susceptibility testing (DST)
Two sputum samples were collected before initiation of anti-TB
treatment and during treatment follow-up. Sputa were shipped to
the Istituto Superiore di Sanita `, Rome, Italy, and processed by the
N-acetyl-L-cysteine-NaOH (NALC) method using a commercial kit
(MycoPrep, Becton Dickinson, Cockeysville, MD). The sediment was
suspended in PBS and inoculated into Lowenstein–Jensen (LJ)
medium (100 ml) (Biome ´rieux, Marcy l’Etoile, France) and BACTEC
MGIT 960 (MGIT) tubes (Becton Dickinson) (500 ml), according to
the manufacturer’s instructions. LJ slants were incubated at 37  Ci n
5% CO2 and examined weekly for 8 weeks. MTB strains were iden-
tiﬁed in positive cultures by DNA probes (Gene Probe, San Diego,
Ca).11,13 DST was carried out for ﬁrst-line (isoniazid, rifampicin,
streptomycin, ethambutol) and second-line (oﬂoxacin, kanamycin,
capreomycin, ethionamide, p-aminosalicylic acid, cycloserine) anti-
TB drugs. DST for ﬁrst-line anti-TB drugs was performed using the
MGIT system; DST for second-line drugs was performed using the
proportion methods on 7H10 as previously described.11 Isolated
strains were stored at  80  C in Brain Heart Infusion broth con-
taining 20% glycerol and shipped to the Research Centre Borstel,
Germany, for molecular typing. Drug-resistance case deﬁnitions
followed WHO case deﬁnitions.14 Extensively drug-resistant
(XDR)-TB was deﬁned by resistance to isoniazid and rifampicinplus
resistance to any ﬂuoroquinolone and at least one of three inject-
able second-line drugs (amikacin, kanamycin, capreomycin).
2.4. Molecular typing
Extraction of genomic DNA from mycobacterial strains and DNA
ﬁngerprinting, using IS6110 as a probe, were performed according
to a standardized protocol.15 Additionally, all isolateswere analysed
by the spoligotyping technique.16 Molecular typing data were
analysed with Bionumerics software (version 4.5; Applied Maths,
Sint-Martens-Latem, Belgium). Spoligotyping data were used to
additionally conﬁrm strain relationships and for genotype classiﬁ-
cation according to SpolDB417 and the MIRU-VNTRplus webpage.18
Patients withmixed patternsindicating a double infectionwithtwo
MTB strains were excluded from further analysis since no clear
IS6110 band deﬁnitionwas possible in mixed-strain isolates. For the
clusteranalysis,a cluster was deﬁned asa minimumof twobaseline
(follow-up strains excluded) strains harbouring identical genotype
pattern from different patients belonging to the study population.
2.5. Statistical analysis
Clinical and laboratory data were entered into a database using
a SQLServer (Microsoft Visual Studio.NET 7$0) and analysed in
StataSE, 9th version, College Station, TX. Only patients’ clinical
and laboratory data at the time of TB diagnosis, before starting
treatment, were evaluated. Results were presented for the whole
study population and for groups of patients with different drug
susceptibility patterns. Chi square (c2) test was used for compar-
ison of proportion. Median (range) and mean (SD: standard devi-
ation) were calculated, and T independent samples-test was used
for comparison of means. P values <0.05 were considered signiﬁ-
cant. Logistic regression analysis was performed to identify
patients’ (age, gender, TB treatment history and prisoner history)
and MTB strains’ (genotype and belonging to a cluster) variables
independently associated with MDR-TB. Similar analysis was
performed to identify association between patients’ variables, MTB
genotype and clustering and between patients’ variables and MTB
genotype. For such analysis, the quantitative variable age was split
into four subgroups (<30, 30–39, 40–49 and  50 years). Because
therewereveryfewmissingobservations, theywereexcluded from
the analysis.
3. Results
Out of 405 consecutive notiﬁed smear-positive TB patients
between March 2003 and September 2005, a total of 366 (90.4%)
cases were screened. Of these, 326 were included in the study
(Figure 1). Mean age was 41 years old (SD 14.1), 77.3% (252/326) of
patients were male and 3.4% (11/326) prisoners. Twelve percent
(38/324) were ex-prisoners and 39.3% (127/323) were previously
treated cases (PTC).
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4. Drug-resistance
Data on resistance of the 326 strains to ﬁrst-line drugs are
presented in Table 1. Drug-resistance was more frequent among
PTC, 68.5% (87/127) than among new cases (NC), 54.1% (106/196),
P¼0.01. Overall, MDR strains were isolated from 68 patients (21%):
8.7% from NC and 38.6% from PTC.
Data on resistance to second-line drugs among MDR-TB patients
are presented in Table 2. Overall, 39 (57.3%) MDR-TB patients had
isolates that were also resistant to one or more second-line drugs.
PTC isolates were more often resistant to second-line drugs (33/49,
67.5%) than NC isolates (6/17, 35.3%), P¼0.02. The frequency of
XDR-TB among MDR-TB patients was 4.4% (3/68); all 3 XDR-TB
patients were PTC.
5. Molecular typing
In general, a high degree of diversity of IS6110 DNA ﬁngerprint
and spoligotyping patterns was observed among the 323 strains
analysed (for three strains, DNA isolation was not successful). For
311 isolates (96.3%), single molecular typing patterns were
obtained, while 12 strains (3.8%) showed mixed patterns demon-
strating a double infection with two MTB strains (data not shown).
Since no clear IS6110 band deﬁnition is possible in mixed-strain
isolates, the patients with mixed infections were excluded from
further investigations.
Among the 311 strains included in the ﬁngerprint analysis, 78
(25.1%) showed the typical Beijing genotype spoligotype and IS6110
RFLP patterns. (Figure 2). However, two clearly different groups of
strains could be identiﬁed within the Beijing branch: one showing
RFLP patterns identical or similar to the W strain family (group 1 in
Figure 2), and the other with clearly distinct RFLP patterns which
have been previously described for strains from other parts of the
former Soviet Union (group 2 in Figure 2).19 Furthermore, a third
group of strains had a spoligotype typical for Beijing genotype but
an IS6110 RFLP pattern less similar to the other Beijing strains
(group 3 in Figure 2).
In addition, ouranalysis revealed the presence of a second group
of closely related isolates of a previously unknown genotype, which
was named ABK-1. Comparison with previous strain classiﬁcations,
based on spoligotyping (SpolDB4, MIRU-VNTRplus webpage),
revealed that the majority of strains had a spoligotype pattern
characteristic of the Latin American Mediterranean (LAM) lineage
of the TB complex.17 Overall, 64/311 strains (20.6%) were ABK-1
strains.
General characteristics of Beijing and ABK-1 strains are pre-
sented in Table 3. Males (P¼0.05) and PTC (P<0.001) were both
366 screened cases
DST and spoligotyping results
Problem of shipment: 11
Culture contamination: 1
Strain contamination: 2
Negative culture: 26
405 notified cases during the
No DNA isolated: 3
Mixed molecular patterns:12
Molecular typing analysis
N= 311 patients
N= 326 strains 
N= 366 strains
study period 
Figure 1. Study proﬁle.
Table 1
First-line anti-TB drug resistance in 326 MTB strains.
New cases Previously
treated cases
Total
No. % No. % No. %
Total tested 196 127 326*
Fully sensitive 90 45.9 40 31.5 131 40.6
Any resistance 106 54.1 87 68.5 195 60.4
Any H resistance 59 30.1 74 58.3 135 41.8
Any R resistance 17 8.7 51 40.2 69 21.4
Any E resistance 36 18.4 50 39.4 88 27.2
Any S resistance 75 38.3 67 52.8 144 44.6
Monoresistance
H only 18 9.2 9 7.1 27 8.4
R only 0 0 1 0.8 1 0.3
E only 12 6.1 7 5.5 19 5.9
S only 25 12.8 4 3.1 29 9.0
H and R resistance
MDR 17 8.7 49 38.6 68 21.0
HþR only 1 0.5 2 1.6 3 0.9
HþRþS only 5 2.6 12 9.5 17 5.3
HþRþEþS only 11 5.6 35 27.6 48 14.9
Other patterns
HþE only 0 0 1 0.8 1 0.3
HþS only 21 10.7 8 6.3 29 9.0
HþEþS only 3 1.5 7 5.5 10 3.1
RþS only 0 0 1 0.8 1 0.3
EþS only 10 5.1 0 0 10 3.1
Number of resistant drugs
1 drug 55 28.1 21 16.5 76 23.3
2 drugs 32 16.3 12 9.5 44 13.5
3 drugs 8 4.1 19 15.0 27 8.3
4 drugs 11 5.6 35 27.6 48 14.7
S: streptomycin; H: isoniazid; R: rifampicin; E: ethambutol.
* 3 Cases without patient’s type information.
Table 2
Second-line anti-TB drug resistance in 68 MDR MTB strains, according to patient
type.
New cases
n¼17*
Previously
treated
cases
n¼49*
Total
N¼68
No. % No. % No. %
No resistance to second-line drugs 11 64.7 16 32.6 29 42.6
Any resistance to second-line drugs 6 35.3 33 67.3 39 57.3
Ethionamide 5 29.4 20 40.8 25 36.8
Kanamycin 3 17.6 18 36.7 21 30.9
Capreomycin 0 0 3 6.1 3 4.4
Oﬂoxacin 0 0 3 6.1 3 4.4
Resistance to >3 second-line drugs 0 0 2 4.1 2 2.9
XDR strains 0 0 3 6.1 3 4.4
* 2 cases without patient-type information.
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at elevated risk of being infected with a Beijing strain. The
proportion of drug-resistance is presented according to MTB
genotypes in Table 4. An elevated frequency of drug resistance
was found among Beijing genotypes when compared with ABK-1
genotype (Table 4).
6. Cluster analysis
Similarity analysis of strains genotyping patterns identiﬁed 165/
311 patients (53.2%) with clustered baseline strains grouped in 44
clusters ranging in size from 2–14 strains (median of 3 strains per
Figure 2. IS6110 DNA ﬁngerprint patterns, spoligotype patterns, and drug-resistance proﬁles of the 311 strains analysed. Banding patterns are ordered by similarity in a dendrogram
as outlined in the materials and methods section. Resistance is displayed by a gray box. Abbreviations: S, streptomycin; I, isoniazid; R, rifampicin; E, ethambutol; O, oﬂoxacin;
C, capreomycin; K, kanamycin; Et, ethionamide; Cs, cycloserine; P, para-aminosalicyclic acid.
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cluster). The Beijing genotype (OR 2.7; 95% CI 1.4–4.8) was signiﬁ-
cantly associated with clustering after multivariate analysis, which
included the age, gender, the prisoner history, the TB treatment
history and the MTB genotype as covariates. In general, a positive
correlation exists between the drug-resistance proﬁles among
strains in one cluster, suggesting a signiﬁcant rate of recent trans-
mission of resistant and MDR strains in the study region (Figure 3).
It should also be noted that the largest cluster (cluster 5), with 14
strains, is formed by a Beijing MDR strain. The fact that all cluster 5
strains are at least MDR, support the notion that this strain is
spreading already being MDR and thenpotentially develops further
resistances. Indeed, seven cluster 5 strains showed resistance to at
least on second-line drug (Figure 3).
7. Patients’ and strains’ characteristics associated with
MDR-TB
The results of the MDR-TB risk factors analysis are presented in
Table 5. No signiﬁcant difference was observed for mean age
between MDR-TB (40.4, SD 12.9) and non-MDR-TB patients (43.0,
SD 14.7; P¼0.17). The strong association between MDR-TB and
clustering was not maintained after adjustment with Beijing
infection in multivariate analysis.
The most striking association found, however, was the enhanced
risk of patients with Beijing infection having MDR-TB (OR 25.9; 95%
CI 10.2–66.0). In new cases, 10 (32.3%) of 31 Beijing strains were
MDR compared with 5 (3.2%) of 157 non-Beijing strains (P<0.001).
For PTC, the difference was 34/45 (75.6%) compared with 10/75
(13.3%), respectively (P<0.001).
Infection with strains of the ABK-1 genotype (OR 4.0; 95% CI
1.3–12.5) and history of previous anti-TB treatment were also
associated with MDR-TB (OR 6.0; 95% CI 2.7–12.9).
8. Discussion
Few population-based studies are available describing the
molecular determinants of the TB epidemic, including clinical and
genotypic strain characteristics, in countries of the former Soviet
Union. None are in Georgia or neighbouring Caucasian countries. In
this study, a systematic investigation of clinical, epidemiological,
and bacteriological characteristics of more than 90% of all smear-
positive pulmonary TB cases could be carried outover a 3-year time
period in Abkhazia.
We report a high rate of drug resistance and speciﬁcally multi-
drug resistance in both newly infected and previously treatedcases,
which is in agreement with observations reported from other
former Soviet Union countries.1,2,5,8 Even more worrying is the fact
that, despite 100% coverage with standard short-course chemo-
therapy (DOTS) since 1999 and full access to free individualized
drug-resistance treatments (including second-line drugs) since
2001, no reduction in MDR-TB was seen when compared with MDR
rates from previous investigations in the same region (4% MDR
prevalence in Abkhazia during the period 2000–2002).1,11 This may
be related to our ﬁndings, which conﬁrm a signiﬁcant association
between Beijing genotype infection and MDR-TB as well as a strong
expansion of one particular Beijing MDR-TB clone.
Persistence of prevalent, circulating strains of MDR-TB are likely
linked to several conditions. First, the collapse of the Soviet Union,
followed by the war and a long chronic conﬂict, has likely
contributed to the current MDR situation in Abkhazia. Second,
a number of factors directly related to MDR, such as the longer
treatment duration, the lower cure rates, and higher default rates,
compared with non-MDR-TB patients may result in greater infec-
tiousness.20,21 The conﬁrmed existence of resistance to second-line
drugs in Abkhazia may also result in difﬁculties to treat MDR-TB,
further extending the period of infectivity.11 All these factors are
likely to favour the spread of MDR-TB in this region.
In Abkhazia, there was no access to rapid DSTor molecular tests
during the study period. Therefore, MDR-TB patients started their
adapted treatment with 2–3 months delay, waiting for DST results.
Such delays in receiving effective treatment may also contribute to
the transmission of drug resistance and is likely to increase the risk
of nosocomial transmission in settings where patients are hospi-
talised during the intensive phase of treatment. Furthermore,
polydrug-resistant patients (10% in our study) who receive stan-
dardized ﬁrst-line regimens until reading of DST results are at risk
of drug-resistance ampliﬁcation.20
Table 3
Patients’ characteristics associated with infection by Beijing and ABK-1 strains,
N¼311.*
Characteristics Univariate analysis Multivariate analysis
% OR 95% CI P value OR 95% CI P value
Beijing strains (n¼78)
Gender
Male 28.3 2.4 1.2–5.1 0.01 2.2 1.0–4.8 0.05
Female 14.1 1
Age (years)
 30 28.6 1
30–39 21.2 0.7 0.3–1.5 0.33
40–49 34.8 1.3 0.6–2.8 0.43
 50 16.3 0.5 0.2–1.1 0.08
Ex-prisoner
Yes 16.7 0.6 0.2–1.4 0.22
No 26.4 1
Patient type
Previously treated case 37.5 3.0 1.7–5.0 <0.001 3.0 1.8–5.2 <0.001
New case 16.5 1
ABK-1 strains (n¼64)
Gender
Male 21.2 1.2 0.6–2.4 0.59
Female 18.1 1
Age (years)
 30 30.4 1
30–39 26.2 0.8 0.4–1.7 0.6
40–49 17.9 0.5 0.2–1.1 0.09
 50 11.6 0.3 0.1–0.7 0.01 NS
Ex-prisoner
Yes 27.8 1.6 0.7–3.5 0.24
No 19.4 1
Patient type
Previously treated case 19.2 0.9 0.5–1.6 0.65
New case 21.3 1
NS: not signiﬁcant.
* A total of 311 patients were included in this analysis, after exclusion of 12 strains
with double infection: 78 patients infected with a Beijing strain compared to 233
infected with a strain of another genotype; 64 patients infected with a strain of ABK-
1 genotype compared to 247 patients infected with a strain of another genotype.
Only covariates presented in the table were included in the multivariable analysis.
Table 4
Proportions of resistance to 1st line antituberculosis drugs according to the MTB
genotype.
N¼311 Beijing strain ABK-1 strain
n % n %
Resistance to
- 0 drug 129 12 9.3 32 24.8
- 1 drug 73 10 13.7 10 13.7
- 2 drugs 42 5 11.9 13 30.9
- 3 drugs 23 14 60.9 4 17.4
- 4 drugs 44 37 84.1 5 11.4
P value* <0.001 0.07
* Trend Pearson chi square.
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A further factor contributing to the high MDR-TB prevalence
seen in Abkhazia might be the prevalence (25%) of patients
infected by Beijing genotype strains. As reported in other former
Soviet Union countries, Beijing genotype was also strongly
associated with MDR-TB in Abkhazia.3,8,22 A possibly higher
capacity of Beijing genotype to develop further drug resistance
compared with strains of other genotypes might result in
a selective advantage for Beijing genotype strains in regions
with high levels of drug resistance. Beijing genotype may
therefore be one of the major contributors to the development
and spread of TB drug resistance here and in other Eastern
European countries.
Figure 3. IS6110 DNA ﬁngerprint patterns, spoligotype patterns, and drug-resistance proﬁles of the 165 strains in clusters. Resistance is displayed by a gray box. Abbreviations: S,
streptomycin; I, isoniazid; R, rifampicin; E, ethambutol; O, oﬂoxacin; C, capreomycin; K, kanamycin; Et, ethionamide; Cs, cycloserine; P, para-aminosalicyclic acid.
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Beijing genotype was also associated with clustering. This
association was also described in Uzbekistan and Singapore.8,9
Noteworthy, the spread of some Beijing strains in correlation with
MDR was exceptional, as shown by strain cluster 5, which was
responsible for 14 MDR-TB cases in the study period. The numberof
cases appeared to increase over time as well (data not shown),
demonstrating the risk posed by such strains.
Nevertheless, the prevalence of Beijing genotype is lower in
comparison with that reported for other former Soviet Union
countries, with values as high as 50% in Karakalpakstan region
(Uzbekistan), 66.6% in Samara region (Russia), and 70.4% in
Kazakhstan.3,8,22 This difference might be explained by the identi-
ﬁcation in 20% of all strains of a new genotype ABK-1, with char-
acteristics typical of the LAM lineage of MTB. This genotype was
also independently associated with the risk of MDR-TB. Few data
are available on the epidemiological and molecular characteristics
of the LAM family in former Soviet Union countries and are limited
only to Russia.4,23 In accordance with these reports, our results
conﬁrm that the LAM genotype is prevalent in a former Soviet
Union country, and might contribute to the emergence of MDR-TB.
This possible association is further supported by the fact that the
highly transmissible XDR-TB strain from an ongoing epidemic in
the KwaZulu-Natal region in South Africa also belonged to the LAM
lineage of MTB.24
These data indicate that in areas with existing high levels of TB
drug resistance and presence of strains of particular genotypes,
current diagnostic and treatment strategies mayactually favour the
selection of highly transmissible MDR, and even XDR, clones,
resulting in large TB outbreaks and ongoing transmission.24 As in
Abkhazia, these speciﬁc MTB strains have the potential to jeopar-
dize TB control efforts in affected areas, and worldwide, if a longer
time scale is considered.
Our risk factor analysis for MDR-TB was limited to the few
patient characteristics collected in this observational study. We
regret the absence of patients’ residence addresses, which did not
allow further investigation of local resistance transmission in the
region. Furthermore, we could not identify the proportion of
patients coming from neighbouring countries, who might have
been admitted into the program during the study period. Indeed, at
the time, Abkhazia was the only place with access to MDR-TB
treatment free of charge in this region of the Caucasus and likely
attracted patients from neighbouring countries, who failed ﬁrst-
line therapies. This explanation could account for the increase in
MDR-TB over time among PTC. Nevertheless, identiﬁcation of such
patients remains difﬁcult because patients may give a false or
relative’s address in order to be admitted into the program, which
technically was limited to patients living in Abkhazia.
In conclusion, our study results show the difﬁculty to control
MDR-TB in a region with pre-existing high prevalence despite the
availability of treatment for drug-resistance tuberculosis in the
region. This can be partially attributed to the high rate of Beijing
genotype strains, and its strong association with both MDR and
transmission, which are likely to be the major contributor to the
spread of TB drug resistance. Thus, new approaches are urgently
needed to more rapidly detect MDR-TB followed by selection of
patients and adapted treatment in order to interrupt the ongoing
transmission of such strains in the community in former Soviet
Union countries.
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